文献速递生殖医学

双通路抑制卵泡激活完全预防环磷酰胺诱导的卵巢储备丧失

Dual suppression of follicle activation pathways completely prevents the cyclophosphamide-induced loss of ovarian reserve.
PubMed 文献 · Hum Reprod · 2023-01-01

该研究在小鼠离体和在体实验中探讨替西罗莫司(Tem)与重组抗苗勒管激素C端(rAMH)联合应用对环磷酰胺(Cy)所致卵巢储备丧失的保护作用。结果显示,Cy单用导致原始卵泡(PMF)储备显著丢失(32±2.12 vs 对照144±2.8,P<0.001),而Tem+rAMH联合治疗完全预防了PMF丢失,与未处理动物无显著差异,主要通过抑制PMF激活、次要通过减少凋亡实现。

要点

  • Cy单用使小鼠PMF储备显著降至32±2.12(对照144±2.8,P<0.001)。
  • Cy+Tem+rAMH联合治疗完全保护PMF储备,与未处理组无显著差异。
  • Cy+Tem+rAMH组初级卵泡颗粒细胞Ki-67阳性率16%,低于Cy单用组65%(P<0.001)。

核心结论

  • Tem与rAMH联合给药完全预防Cy诱导的小鼠卵泡耗竭并保护卵巢储备,主要经PMF激活抑制、次要经减少凋亡实现。

研究设计与样本

  • 12日龄小鼠全卵巢离体培养7天,给予Cy±rAMH或Tem。
  • 8周龄小鼠随机分八组:溶剂对照/rAMH/Tem/Cy/Tem+rAMH/Cy+Tem/Cy+rAMH/Cy+Tem+rAMH。
  • 离体实验每组16-18个卵巢,在体实验每组8只小鼠用于卵泡计数。

主要发现

  • 在体实验中Cy单用导致PMF储备显著丢失(32±2.12 vs 对照144±2.8,P<0.001),Tem或rAMH单用均显著减轻该丢失(均P<0.001)。
  • Cy+Tem+rAMH联合治疗完全保护PMF储备,与未处理动物PMF数目无显著差异,离体实验示类似结果。
  • Cy+Tem+rAMH组初级卵泡颗粒细胞Ki-67阳性率16%,低于Cy单用组65%(P<0.001)。
  • Cy单用使rpS6和mTOR磷酸化分别升至对照卵巢的1.9倍和1.4倍(未达统计学显著),Cy+Tem+rAMH组降至对照水平以下(P<0.01)。
  • Cy处理后12 h PMF卵母细胞γH2AX阳性率94%,高于对照59%(P<0.001),Cy+Tem+rAMH组降至69%(P<0.001);Cy组24 h仅22% PMF卵母细胞凋亡,Cy+Tem+rAMH组降至12%(P<0.01)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 实验设计限于选择单一时间点(Cy给药后24 h)分析PMF激活与凋亡,尽管DNA损伤于Cy给药后12 h测定、短期卵泡动力学影响于治疗后3天观察。
  • 蛋白分析在全卵巢裂解液中进行,所发现的蛋白变化无法定位至卵巢内特定细胞。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: To what extent and how does combined administration of the follicle activation pathway suppressive agents temsirolimus (Tem) and c-terminus recombinant anti-Müllerian hormone (rAMH) protect against chemotherapy-induced ovarian reserve loss? SUMMARY ANSWER: Combined administration of Tem and rAMH completely prevents cyclophosphamide (Cy)-induced follicle depletion and protects the ovarian reserve in mice, primarily via primordial follicle (PMF) suppression of activation and to a lesser degree by reducing apoptosis. WHAT IS KNOWN ALREADY: There is conflicting evidence regarding the contributory roles of apoptosis and follicle activation in chemotherapy-induced PMF loss. Tem, a mammalian target of rapamycin (mTOR) inhibitor, reduces activity of the phosphoinositide 3-kinases-phosphatase and tensin homolog (PI3K-PTEN) pathway which provides intrinsic regulation of PMF activation. Anti-Müllerian hormone (AMH), secreted by early growing follicles, is an extrinsic regulator of PMF activation. STUDY DESIGN, SIZE, DURATION: Whole ovaries of 12-day-old mice were cultured ex vivo for 7 days in the presence of Cy ± rAMH or Tem. Eight-week-old mice were randomized into eight treatment groups: vehicle control/rAMH/Tem/Cy/Tem + rAMH/Cy + Tem/Cy + rAMH/Cy + Tem + rAMH. Twelve hours after treatment, ovaries were removed for DNA damage analysis, and 24 h after treatment either for analysis of PI3K pathway proteins or to be fixed and immunostained for analyses of proliferation and apoptosis. Three or 21 days following treatment, ovaries were fixed and sectioned for follicle counting. PARTICIPANTS/MATERIALS, SETTING, METHODS: Hematoxylin and eosin staining was used for differential follicle counts of primordial, primary, and secondary follicles in ex vivo (n = 16-18 ovaries per group) and in vivo ovaries (n = 8 mice per group). Histological analyses were carried out to measure proliferation by quantifying Ki-67-positive granulosa cells in primary follicles (n = 4 mice per group). DNA damage and apoptosis were measured by quantification of phosphorylated form of histone 2AX (γH2AX) and cleaved poly (ADP-ribose) polymerase (cPARP)-positive PMF oocytes, respectively (n = 8 mice per group). Protein extracts from whole ovaries were analyzed by western blotting. MAIN RESULTS AND THE ROLE OF CHANCE: In vivo experiments show that treatment with Cy alone caused significant loss of PMF reserve (32 ± 2.12 versus 144 ± 2.8 in control, P < 0.001), and this was significantly attenuated by treatment with either Tem (P < 0.001) or rAMH (P < 0.001). Combined cotreatment with Cy + Tem + rAMH provided complete protection of the PMF reserve, with no significant difference in numbers of PMF versus untreated animals. Similar results were demonstrated in the ex vivo experiments. Proliferation marker Ki-67 staining was significantly reduced in granulosa cells of primary follicles in the Cy + Tem + rAMH group compared with Cy alone group (after 24 h in vivo administration of Cy, 16% versus 65%, respectively; P < 0.001). Protein analysis demonstrated not significant increased phosphorylation of follicle activation proteins rpS6 and mTOR with in vivo administration of Cy alone (1.9 and 1.4 times the control ovaries, respectively), and this was reduced to below control levels in the Cy + Tem + rAMH group (P < 0.01). The Cy + Tem + rAMH combined cotreatment protected the follicle reservoir via inhibition of Cy-induced upregulation of the PI3K signaling pathway, together with replacement of AMH suppression of PMF activation with rAMH, implying a complementary effect of the two inhibitors. The DNA damage marker γH2AX was highly positive in PMF oocytes from Cy-treated ovaries 12 h after treatment, compared with controls (94% versus 59%, respectively, P < 0.001) and was significantly reduced to (69%) in Cy + Tem + rAMH cotreated ovaries (P < 0.001). However, only 22% of PMF oocytes of the Cy group showed apoptosis at 24 h, and this was significantly reduced (12%) in ovaries after treatment with Cy + Tem + rAMH (P < 0.01). This suggests that it is not possible to equate DNA damage with oocyte death, and also indicates that less than one-third of the total PMF loss can be attributed to apoptosis, implying that most of the PMF depletion results from PMF activation but that both mechanisms play a significant role. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: The experimental design was limited by the selection of one time point for analysis of PMF activation and apoptosis (i.e. 24 h after Cy administration), although DNA damage was measured at 12 h after Cy administration and any impact on short-term follicle dynamics at 3 days after treatment. Protein analysis was conducted on whole ovary lysates therefore the protein changes identified cannot be localized to specific cells within the ovary. However, this complementary assay showed that there was activation in the ovary through massive reduction in the phosphorylation of key proteins in the PI3K cascade (rpS6 and mTOR), which is consistent with the sequence of events after Cy administration. WIDER IMPLICATIONS OF THE FINDINGS: Understanding the complementary nature of different follicle activation pathways and the impact of their suppression in prevention of chemotherapy-induced ovotoxic damage, as well as their involvement in DNA damage inhibition, provides an interesting direction for future research, and the potential for noninvasive pharmacological fertility preservation. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by a grant from the Morris Kahn Foundation. The authors declare no conflicts of interest.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Kashi O, Roness H, Spector I, et al. Dual suppression of follicle activation pathways completely prevents the cyclophosphamide-induced loss of ovarian reserve. Hum Reprod. 2023. PMID: 37015102. doi:10.1093/humrep/dead064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。